Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 ...

PDC*line Pharma, a clinical-stage biotech company developing a new class of immunotherapies for cancers, presented the ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

The new promising data presented by Martin Forster, M.D., Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 ...

To that end, it has even already gone on to report an increase in response rate when Cretostimogene was given in combination ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

Vir Biotechnology's phase 3 hepatitis programs and cancer trials are on the horizon. Read why VIR stock could benefit from ...

Rucaparib Maintenance Improves Long-Term Outcomes in Ovarian Cancer Rucaparib maintenance after first-line chemotherapy and ...